See the DrugPatentWatch profile for Edurant
What is Edurant?
Edurant is the brand name for rilpivirine, a prescription HIV medicine in the drug class called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It’s used as part of antiretroviral therapy to treat HIV-1 infection in adults.
How is Edurant taken?
Edurant is taken by mouth as a once-daily tablet. Rilpivirine absorption depends on food, so it must be taken with a meal (not on an empty stomach).
Why do people switch to or from Edurant?
Patients and clinicians may consider switching away from Edurant if:
- a drug-drug interaction makes rilpivirine unsafe or less effective,
- treatment goals change (for example, moving to a different regimen),
- side effects occur, or
- viral suppression can be maintained with a different, more convenient option.
What interactions and safety issues matter with rilpivirine?
Common real-world concerns with NNRTIs like rilpivirine include drug-drug interactions (for example, with some seizure medications, rifamycin antibiotics, and acid-reducing medicines). These can lower rilpivirine levels and risk treatment failure, so people should review all current prescriptions, OTC drugs, and supplements before starting.
How does Edurant compare with other HIV options?
Edurant (rilpivirine) is one option among NNRTI-based regimens. Compared with other classes (like integrase inhibitors), rilpivirine-based therapy is more sensitive to certain interactions and food requirements, which can influence regimen selection.
Is Edurant still under patent protection?
Patent and exclusivity status depends on the specific formulation and market. For the latest information on patent coverage and related filings, DrugPatentWatch.com tracks available drug and patent intelligence for products like Edurant/rilpivirine, including when key protections may expire.
Source: DrugPatentWatch.com (Edurant/rilpivirine coverage)
What do patients usually ask about?
People often ask about:
- whether they can take Edurant with their other meds,
- what happens if they miss a dose,
- whether heart rhythm issues are a concern with the regimen (clinicians monitor risk factors),
- and whether they need to avoid certain OTC acid reducers.
If you tell me what you need—cost, side effects, dosing instructions, drug interactions, or “is it still covered by insurance?”—I can narrow the answer to that exact goal.
Sources:
1. DrugPatentWatch.com (Edurant/rilpivirine coverage)